CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法治疗胶质母细胞瘤
英文原题：Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma.
查看英文原题
Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是成人最常见的原发性脑肿瘤，其特点是生存率低、预后不良。当前治疗方式包括广泛手术切除、化疗和放疗，但由于大脑对损伤较敏感，这些治疗往往效果有限并导致显著副作用。近期，免疫治疗取得令人振奋的进展，在多种肿瘤治疗中显示出前景，为改善脑肿瘤患者结局带来希望。一种有前景的免疫治疗方法是嵌合抗原受体（CAR）T细胞疗法，该疗法识别靶肿瘤细胞表面蛋白，并将细胞毒作用导向特定靶标。本综述旨在讨论CAR-T 细胞免疫疗法治疗GBM的现有研究及未来前景。
展开英文摘要原文
Glioblastoma (GBM), the most common primary brain tumor in adults, is characterized by low survival rates and a grim prognosis. Current treatment modalities, including extensive surgical resection, chemotherapy, and radiation therapy, often yield limited success due to the brain's sensitivity, leading to significant side effects.
Exciting advancements in immunotherapy have recently shown promise in treating various types of tumors, raising hopes for improved outcomes in brain tumor patients. One promising immunotherapy approach is chimeric antigen receptor (CAR) T-cell therapy, which recognizes surface proteins on targeted tumor cells and redirects cytotoxicity towards specific targets. This review aims to discuss the existing research and future prospects for CAR T-cell immunotherapy in treating glioblastoma.
论文信息
- 作者
- Ma K、Hu P
- 第一作者单位
- Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang 330001, Jiangxi, China.China
- 通讯作者单位
- Institute of Translational Medicine, Nanchang University, Nanchang 330001, Jiangxi, China.China
- 文献类型
- 综述
- 期刊
- Cancers2023 Nov 30
- 原文标识
- PubMed 38067356 · DOI 10.3390/cancers15235652
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →